CAS 1257044-40-8
:ABT-199
- 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
- Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-
- Gdc-0199
- Rg 7601
- Rg7601
- Venclexta
- Venclyxto
- Venetoclax
- ABT 199
- 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide
- GDC0199
- ABT199,GDC0199
- 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide ABT-199 (GDC-0199)
- Weitere Synonyme anzeigen
4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide
CAS:Formel:C45H50ClN7O7SReinheit:99%Farbe und Form:SolidMolekulargewicht:868.4392Venetoclax
CAS:Venetoclax (ABT-199) is a selective inhibitor of Bcl-2 (Ki < 0.010 nM), binding over 3 orders of magnitude less avidly to Bcl-xL, and Bcl-W (Kis = 48/245 nM).Formel:C45H50ClN7O7SReinheit:98.00% - 99.97%Farbe und Form:SolidMolekulargewicht:868.44ABT 199 (>99%)(Venetoclax)
CAS:Kontrolliertes ProduktApplications ABT 199 (>99%) is a potent and selective BCL-2 inhibitor that achieves potent antitumour activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
References Davids, M. & Letai, A.: Cancer Cell, 23, 139 (2013); Souers, A.,et al.: Nat. Med., 19, 202 (2013); Vaillant, F., et al.: Cancer Cell, 24, 120 (2013); Vogler, M., et al.: Brit. J. Haematol., 163, 139 (2013);Formel:C45H50ClN7O7SFarbe und Form:Light Yellow To YellowMolekulargewicht:868.44ABT 199 (Venetoclax)
CAS:Kontrolliertes ProduktApplications ABT 199 is a potent and selective BCL-2 inhibitor that achieves potent antitumour activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
References Davids, M. & Letai, A.: Cancer Cell, 23, 139 (2013); Souers, A.,et al.: Nat. Med., 19, 202 (2013); Vaillant, F., et al.: Cancer Cell, 24, 120 (2013); Vogler, M., et al.: Brit. J. Haematol., 163, 139 (2013);Formel:C45H50ClN7O7SFarbe und Form:Light Yellow To YellowMolekulargewicht:868.44Venetoclax
CAS:A BCL-2 selective inhibitor with no effect on Bcl-xl and thereby prevents thrombocytopenia. Increased sensitivity observed in Bcl-2-dependent haematological tumour cell lines. Elicits additional benefits to tamoxifen treatment in ER-positive breast cancer xenografts.Formel:C45H50ClN7O7SReinheit:Min. 98 Area-%Farbe und Form:Yellow PowderMolekulargewicht:868.44 g/molABT-199-D10
CAS:Kontrolliertes ProduktApplications ABT-199-D10 is a deuterized form of ABT 199 (A112430), which is a potent and selective BCL-2 inhibitor that achieves potent antitumor activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
References Davids, M. & Letai, A.: Cancer Cell, 23, 139 (2013); Souers, A.,et al.: Nat. Med., 19, 202 (2013); Vaillant, F., et al.: Cancer Cell, 24, 120 (2013); Vogler, M., et al.: Brit. J. Haematol., 163, 139 (2013);Formel:C45D10H40ClN7O7SFarbe und Form:NeatMolekulargewicht:878.5







